Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Merck KGaA to Buy Springworks for $3.9B

In This Article:

German pharma company Merck is buying US biotech SpringWorks Therapeutics for $3.9B. SpringWorks makes medicines for cancer and rare diseases and is expected to give a boost to Merck's health-care division. Belen Garijo, Merck KGaA CEO joined Bloomberg Open Interest to talk about the deal.